BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Independent Study Shows Significant Decline in Cardiac Device Infections with TYRX® Antibacterial Envelope
New Data in High Risk Patients Presented at Heart Rhythm Society
Shows a 70% Reduction in CIED Infections
Denver, CO (May 10, 2013): Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular implantable electronic device (CIED) implants, according to a study presented today at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.